Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:
| Location |
FTI Consulting
Holborn Gate
26 Southampton Buildings
London, WC2A 1PB |
| 10.45 |
Registration with refreshments |
| 11.00 |
Introduction David Evans,
Scancell Non-Executive Chairman
|
| 11.05 |
Cancer immunotherapy
Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester
|
| 11.20 |
Scancell corporate update
Dr Richard Goodfellow, Joint CEO of Scancell
|
| 11.30 |
SCIB1 trial update and introduction to Moditope™
Prof Lindy Durrant, Joint CEO of Scancell
|
| 11.45 |
Q&A |
| 12.00 |
Interactive panel discussion
Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital
Panellists include:
Prof Lindy Durrant,
Prof Peter Stern,
Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University
and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton
|
| 12.45 |
Buffet lunch |
| 13.30 |
Close |
For Further Information:
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+ 44 (0) 20 7831 3113 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
| Mo Noonan/Eleanor Clarke |
FTI Consulting |
+ 44 (0) 20 7831 3113 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.